Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Related Keywords

Indonesia ,Shanghai ,China ,United States ,Italy ,Thailand ,Liechtenstein ,United Kingdom ,France ,Iceland ,Israel ,Norway ,Singapore ,Australia ,Malaysia ,Canada ,Taiwan ,Northern Ireland ,Craigavon ,Hong Kong ,South Korea ,Chinese ,Lichtenstein ,Thomas Karalis ,Asia Pacific ,Peter Qian ,Hong Kongchina ,Jay Mei ,Prnewswire Antengene Corporation Limited ,Department Of Health ,Karyopharm Therapeutics Inc ,Antengene Corporation Limited ,Company Named Patient Program ,European Society Of Medical Oncology ,Hong Kong Stock Exchange ,European Union ,International Myeloma Foundation ,Company Annual ,International Myeloma Working Group ,National Cancer Care Network ,Chinese Society Of Clinical Oncology ,Antengene Corporation ,Cancer Association Guidelines For The Holistic ,Taiwan China ,Corporation Limited ,Hong Kong Special Administrative Region ,New Drug Application ,Chinese Society ,Clinical Oncology ,First Relapsed Multiple Myeloma ,Multiple Myeloma ,China Anti Cancer Association ,European Society ,Medical Oncology ,Corporate Vice President ,Named Patient Program ,Karyopharm Therapeutics ,Hong Kong China ,Patients Beyond ,Annual Report ,Hong Kong Stock ,